Paul S. Herendeen

2021 - Valeant Pharmaceuticals International

In 2021, Paul S. Herendeen earned a total compensation of $6.9M as Former Executive Vice President and Chief Financial Officer at Valeant Pharmaceuticals International, a 16% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$1,010,000
Option Awards$1,050,034
Salary$707,692
Stock Awards$4,109,488
Other$21,635
Total$6,898,849

Herendeen received $4.1M in stock awards, accounting for 60% of the total pay in 2021.

Herendeen also received $1M in non-equity incentive plan, $1.1M in option awards, $707.7K in salary and $21.6K in other compensation.

Rankings

In 2021, Paul S. Herendeen's compensation ranked 1,789th out of 12,397 executives tracked by ExecPay. In other words, Herendeen earned more than 85.6% of executives.

ClassificationRankingPercentile
All
1,789
out of 12,397
86th
Division
Manufacturing
663
out of 5,492
88th
Major group
Chemicals And Allied Products
247
out of 2,367
90th
Industry group
Drugs
208
out of 2,090
90th
Industry
Pharmaceutical Preparations
142
out of 1,537
91st

Pay ratio

Paul S. Herendeen's Pay$6,898,849
Median Employee's Pay$44,617
Pay Ratio

155

to 1

In 2021, the annual total compensation of Paul S. Herendeen was $6,898,849.

The annual total compensation of the median employee at Valeant Pharmaceuticals International was $44,617.

The ratio of Paul S. Herendeen's pay to the pay of median employee was therefore 155 to one.

Source: SEC filing on May 2, 2022.

Herendeen's colleagues

We found five more compensation records of executives who worked with Paul S. Herendeen at Valeant Pharmaceuticals International in 2021.

2021

Joseph Papa

Valeant Pharmaceuticals International

Chief Executive Officer

2021

Thomas Appio

Valeant Pharmaceuticals International

President Co, Head Bausch + Lomb/International

2021

Christina Ackermann

Valeant Pharmaceuticals International

General Counsel

2021

Sam Eldessouky

Valeant Pharmaceuticals International

Chief Financial Officer

2021

Robert Spurr

Valeant Pharmaceuticals International

President, U.S. Pharma Business

News

You may also like